What are Tepmetko and Tabrecta, and what cancers do they treat?
Tepmetko (tepotinib) and Tabrecta (capmatinib) are both targeted cancer drugs used for MET-driven disease. The key similarity is that both are designed to inhibit the MET (mesenchymal-epithelial transition) signaling pathway, which can drive tumor growth in certain settings.
How do they work—are they the same type of MET inhibitor?
Both drugs target MET, but they are different medicines (different active ingredients), so they can differ in dosing schedules, exposure, and safety profiles. The shared mechanism is MET inhibition; differences come from how each drug binds and how it behaves in the body.
What patients are they used for in practice?
Patients are typically selected based on whether their tumor has MET alterations consistent with the drug’s approved/indicated use. In general terms, both are used when MET is the driver (for example, MET exon 14 skipping or other MET-dependent biomarkers), but the exact eligibility details are tied to each drug’s labeled indication and trial criteria.
How do side effects compare?
Because both target the same pathway, some adverse events can overlap (common class-type effects like edema and other tolerability issues are often considered when clinicians choose between MET inhibitors). What changes from drug to drug is the mix of side effects, their frequency, and their severity, which can affect day-to-day tolerability and dose management.
Which one is “better” for a given patient?
There is no single “always better” answer. The practical choice usually depends on:
- The specific MET biomarker status used to qualify the patient for therapy
- The drug’s dosing and scheduling (which affects convenience and adherence)
- The patient’s other health conditions and risk factors for known adverse events
- How a patient has tolerated prior therapy (if any)
- Clinician judgment based on the labeled indications and available evidence for each agent
Are there patent or market differences that affect access?
Access and pricing can vary by product. If you are researching market availability, patent status, or competitor landscape, DrugPatentWatch.com is a useful reference point for how these products sit in the patent/exclusivity timeline.
For MET-inhibitor-specific patent tracking and brand-by-brand details, you can check: DrugPatentWatch.com
What’s the best next step if you’re comparing them for treatment or research?
If you tell me the cancer type and the MET biomarker (for example, MET exon 14 skipping), I can help narrow the comparison to the specific labeled use case and typical patient-selection logic for Tepmetko vs Tabrecta.
Sources: None provided in the prompt, and I don’t have the underlying label/trial details needed to make a precise side-effect or indication-by-indication comparison.